Yonsei University

Jiyeon Kweon

Dong Wook Kim

Jin Soo Kim

Jung Eun Kim

Chul Yong Park

Duk Hyoung Kim

The present invention provides a method for inducing an inversion of normal blood coagulation factor VIII (F8) gene, a method for correcting an inversion of blood coagulation factor VIII gene in which the inversion has occurred, and a Hemophilia A patient-derived induced pluripotent stem cell in which the inversion is corrected, constructed using the same. The method of the present invention effectively reproduces the inversion of intron 1 and intron 22 of the F8 gene, which is responsible for the majority of severe hemophilia A, and thereby may be effectively used for studying the development mechanism of hemophilia A and as a research tool for screening therapeutic agents. The inversion-corrected induced pluripotent stem cell constructed according the method of the present invention enables an efficient and fundamental treatment for hemophilia A by restoring a genotype in which mutation has occurred to a wild type-like state, without limitation via normal gene or protein delivery.

RNA guided endonuclease targeting blood coagulation factor VIII intron 1 inversion gene and composition for treating hemophilia comprising same

Talen targeting blood coagulation factor VIII intron 1 inversion gene and composition for treating hemophilia comprising same

Endonuclease targeting blood coagulation factor VIII gene and composition for treating hemophilia comprising same

Growing community of inventors

Seoul, South Korea

Jiyeon Kweon